Cancer Communications
indexed by SCI
BMC

Review
China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy
Ming Zhou, Xiaoyuan Chen, Hong Zhang, Lin Xia, Xin Tong, Limin Zou, Ruimin Hao, Jianhong Pan, Xiao Zhao, Dongmei Chen, Yuanyuan Song, Yueli Qi, Ling Tang, Zhifang Liu, Rong Gao, Yuankai Shi and Zhimin Yang
Medical Review Department 1, Center for Drug Evaluation, China National Medical Products Administration, No. 128 Jianguo Road, Chaoyang District, Beijing, 100022, P. R. China
[Abstract]

Background
On May 8, 2018, the China National Medical Products Administration (NMPA) approved anlotinib, an orally administered anti-angiogenesis inhibitor, for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who have progressed after treatment with two or more lines of prior systemic chemotherapy.
Main body of the abstract
China NMPA reviewed and inspected a regional double-blinded, placebo-controlled, Phase III trial comparing the overall survival (OS) of NSCLC patients between the anlotinib and placebo arms. A total of 437 patients were randomized (2:1) to receive either anlotinib (n = 294) or placebo (n = 143) once daily on a 2-week on and 1-week off schedule. Patients with epidermal growth factor receptor (EGFR) or activating anaplastic lymphoma kinase (ALK) genomic tumor aberrations should have disease progression on NMPA-approved therapy. Anlotinib is the first NMPA-approved drug for patients with advanced NSCLC who have progressed on at least two lines of prior systemic chemotherapies in China. The approval was based on a statistically and clinically significant improvement in median OS with anlotinib (9.46 months) compared with placebo [6.37 months; hazard ratio (HR]) = 0.70, 95% confidence interval (CI) = 0.55?C0.89; two-sided log-rank P = 0.002]. The confirmed objective response rate (ORR) was 9.2% in the anlotinib arm and 0.7% in the placebo arm. The median duration of response (DoR) was 4.83 months, with a 95% CI of 3.31?C6.97 months. The toxicity profile of anlotinib was consistent with that of known anti-angiogenesis inhibitors. Common adverse drug reactions (ADRs) in anlotinib-treated patients included hypertension (67.4%), hand?Cfoot syndrome (43.9%), hemoptysis (14.0%), thyroid stimulating hormone (TSH) elevation (46.6%), and corrected QT interval (QTc) prolongation (26.2%).
Short conclusion
Anlotinib demonstrated a clinically significant OS prolongation as a novel therapeutic option for advanced or metastatic NSCLC following at least two lines of chemotherapy.
Cancer Communications   Epub date: 6/20/2019   doi:10.1186/s40880-019-0383-7
[PDF Full-text]

[ Html full-text] (BioMed Central)

[ PubMed]

Cite this article

Ming Zhou, Xiaoyuan Chen, Hong Zhang, Lin Xia, Xin Tong, Limin Zou, Ruimin Hao, Jianhong Pan, Xiao Zhao, Dongmei Chen, Yuanyuan Song, Yueli Qi, Ling Tang, Zhifang Liu, Rong Gao, Yuankai Shi and Zhimin Yang. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy. Cancer Commun (Lond). 2019, 39:36. doi:10.1186/s40880-019-0383-7


Export citations

EndNote

CJC Wechat 微信公众号


 

Editorial Manager


CC adopts Editorial Manager to manage its submissions from Dec.18, 2014

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by BioMed Central

© Cancer Communications

651 Dongfeng Road East, Guangzhou 510060, P. R. China